Market is one of the leading causes of irreversible vision loss in individuals aged 50 and above. With the global aging population increasing rapidly, the burden of AMD is escalating, pushing the ...

Fintel reports that on June 17, 2025, RBC Capital initiated coverage of EyePoint Pharmaceuticals (NasdaqGM:EYPT) with a ...

Partner: Aura Biosciences Title: Bel-sar - a New Treatment Paradigm in Choroidal Melanoma: Update on the Global Phase 3 CoMpass Trial Presented by: Jennifer Lim, MD, Professor of Ophthalmology, ...

In this video, Peter K. Kaiser, MD, founding director of the Digital Eye Optical Coherence Tomography Reading Center at the Cole Eye Institute, discusses treatment options for wet age-related macular ...

Axpaxli is Ocular's main value driver, targeting a large wet AMD market with a differentiated, sustained-release TKI ...

Comprehensive Age-related Macular Degeneration Market Analysis: Trends and Developments Across All Types According to DelveInsight’s analysis, the market for age-related macular degeneration is ...

RetinalGenix Technologies Inc.OTCQB:RTGN (“RetinalGenix” or the “Company”), a pioneer in advanced retinal imaging and precision medicine, is pleased to announce the ...

Outlook Therapeutics, Inc. (Nasdaq: OTLK), today announced the Scottish Medicines Consortium (SMC) approval of LYTENAVA™ (bevacizumab gamma) for the treatment of wet age-related macular degeneration ...

The Scottish Medicines Consortium (SMC) has accepted Outlook Therapeutics’ Lytenava to treat wet age-related macular ...

ISELIN, N.J., June 10, 2025(Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the Scottish Medi ...